| Monoclonal antibody | |
|---|---|
| Source | humanized |
| CCR5 | |
| Identifiers | |
| CAS number | ? |
| ATC code | none |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
PRO 140 is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of HIV infection.[1]
The United States Food and Drug Administration has designated PRO 140 for fast-track approval.[2] In February 2008, the drug entered Phase 2 clinical trials.[3]
Contents |
Development
PRO 140 is being developed by Progenics Pharmaceuticals. In May 2007, they announced results from the phase I clinical trial of the drug. The researchers said the results demonstrated "potent, rapid, prolonged, dose-dependent, highly significant antiviral activity" for PRO 140. Participants in the highest dosing group received 5 mg/kg and showed an average viral load decrease of -1.83 log10. On average, reductions of greater than -1 log10 copies/ml were maintained for between two and three weeks, from only a single dose of the drug.[4] The largest individual HIV RNA reductions ranged up to -2.5 log10 among patients receiving both the 2 and 5 mg/kg doses.[5]
Mechanism of action
PRO 140 functions as an entry inhibitor.[6][7] PRO 140 binds to the CCR5 receptor, and interferes with HIV's ability to enter the cell. Unlike other entry inhibitors, PRO 140 is a monoclonal antibody. As such, it must be injected to be effective. However, once inside the body, PRO 140 binds to CCR5 for >60 days,[1] which may allow for dosing as infrequently as every other week.[8][9]
See also
External links
References
- ^ a b Progenics Pharmaceuticals' HIV Drug, PRO 140, Receives FDA Fast-Track Designation. Press release, 22 Feb 2006. Progenics Pharmaceuticals.
- ^ Brian Lawler. Progenics' Intriguing Study Results. The Motley Fool. 2 May 2007.
- ^ "Phase 2 clinical trials started on PRO 140". AIDS Patient Care STDS 22 (2): 159–60. February 2008. PMID 18273941.
- ^ Derek Thaczuk. ICAAC: Phase 1 study provides `proof of concept` for PRO 140, a monoclonal CCR5 antibody. AIDSmap.com. 21 Sept 2007.
- ^ Liz Highleyman. Monoclonal Antibody CCR5 Inhibitor PRO 140 Produces Long-lasting HIV Suppression in Single-dose Study. 28 Sept 2007. HIVandHepatitis.com
- ^ Biswas P, Tambussi G, Lazzarin A (2007). "Access denied? The status of co-receptor inhibition to counter HIV entry". Expert Opin Pharmacother 8 (7): 923–33. doi:. PMID 17472538. http://www.expertopin.com/doi/abs/10.1517/14656566.8.7.923.
- ^ Pugach P, Ketas TJ, Michael E, Moore JP (August 2008). "Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors". Virology 377 (2): 401–7. doi:. PMID 18519143. http://linkinghub.elsevier.com/retrieve/pii/S0042-6822(08)00272-9.
- ^ PRO 140. Progenics Pharmaceuticals.
- ^ Tim Horn. Single-Dose PRO 140 Has Lasting Effects. 21 Sept 2007. POZ.com.
|
|||||||||||||||||||||||||||||
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
